|
Last Updated: Apr 16, 2008 - 5:52:06 PM |
Neupro (rotigotine transdermal system)
-
Audience: Neurologists, other healthcare professionals, patients
[Posted 04/09/2008] Schwarz Pharma informed healthcare professionals
and patients of the recall of Neupro, a transdermal delivery system
worn on the skin and used to treat early stage Parkinson’s disease, at
the end of April 2008, because of the formation of rotigotine crystals
in the patches. When the drug crystallizes, less drug is available to
be absorbed through the skin and the efficacy of the product may vary.
Healthcare professionals should not initiate any new patients on Neupro
and should begin to down-titrate all patients currently using the
product per the guidelines in the product labeling. Patients should NOT
abruptly discontinue therapy. Abrupt withdrawal of dopamine agonists
has been associated with a syndrome resembling neuroleptic malignant
syndrome or akinetic crises.
[April 8, 2008 - Drug Shortage Information - FDA.]
© 2004-2008 by foodconsumer.org unless otherwise specified
Top of Page
